SOURCE: Lightstone Ventures

Lightstone Ventures

March 02, 2016 08:56 ET

Lightstone Ventures Names Stacy Enxing Seng as Venture Partner

Medical Device Industry Veteran Brings Proven Track Record, Deep Operational, Leadership Skills

MENLO PARK, CA and BOSTON, MA--(Marketwired - Mar 2, 2016) - Lightstone Ventures (LSV) today announced the appointment of Stacy Enxing Seng as Venture Partner. In this role, she will assist the LSV medical device team with deal sourcing, due diligence, and portfolio company growth and management.

"Stacy is one of the most respected leaders in the medical device industry, and it is an honor to welcome her to the Lightstone team," said LSV General Partner Mike Carusi. "She has established a proven track record for leading technologies and companies from early concept and development through global market leadership. Her experience and vast network of relationships across the technical, clinical, and entrepreneurial communities, as well as her background working with strategic investors, will be of tremendous value to the LSV team and our portfolio."

Carusi continued, "While many in the venture community are scaling back their investments in medical devices, we are expanding our portfolio and our team, and strengthening our focus. With an uptick in interest from strategic investors, the recent successful exits of legacy portfolio companies Twelve and Transcend, and new investments in five promising medical device companies, we remain confident about the future of this space."

Enxing Seng currently serves as a Member of the Board of Directors for several public and private companies including Hill-Rom (NYSE: HRC), Sonova AG (SIX: SOON), Solace Therapeutics and Spirox Inc. Previously, she served as President of Covidien's $1.7B Vascular Therapies business. She joined Covidien following its $2.6B acquisition of ev3 Inc., a successful medical technology start-up where she was a member of the founding team. Over the course of her career, Enxing Seng has been involved in the launch of over 20 medical technologies and more than 10 substantive M&A transactions. Earlier in her career, she held various positions at other high profile medical technology companies including Boston Scientific, SCIMED Life Systems, Baxter Healthcare and American Hospital Supply.

"After working in the medical technology industry for almost 30 years, I'm delighted to join Lightstone during what I believe is an optimal time to be investing in medical devices, " said Stacy Enxing Seng. "The firm is well positioned to play an important role to advance new devices and treatments ultimately improving the quality of healthcare and patient outcomes."

Enxing Seng is a frequent speaker at industry events and has been named one of the Top 100 Women in Business. She received a Master of Business Administration from Harvard University and has a Bachelor of Arts in Public Policy from Michigan State University.

About Lightstone Ventures
Lightstone Ventures (LSV) was founded in 2012 by the General Partners of the life science teams at Advanced Technology Ventures (ATV) and Morgenthaler Ventures to invest in early-stage breakthrough medical device and biopharmaceutical companies that have the potential to change medicine. Members of the Lightstone team have been involved in several of the largest, venture-backed life science exits over the last decade. The firm now has offices in the U.S., Europe, and Asia. For more information, visit www.lightstonevc.com.

Contact Information

  • For further information, please contact:
    Donna von Halle
    Email Contact
    781.771.4574